Lysosomal Trafficking Regulator (LYST).
Document Type
Article
Publication Date
2016
JAX Location
Reprint Collection
JAX Source
Adv Exp Med Biol 2016; 854:745-50.
Volume
854
First Page
745
Last Page
750
ISSN
0065-2598
PMID
26427484
Abstract
Regulation of vesicle trafficking to lysosomes and lysosome-related organelles (LROs) as well as regulation of the size of these organelles are critical to maintain their functions. Disruption of the lysosomal trafficking regulator (LYST) results in Chediak-Higashi syndrome (CHS), a rare autosomal recessive disorder characterized by oculocutaneous albinism, prolonged bleeding, severe immunodeficiency, recurrent bacterial infection, neurologic dysfunction and hemophagocytic lympohistiocytosis (HLH). The classic diagnostic feature of the syndrome is enlarged LROs in all cell types, including lysosomes, melanosomes, cytolytic granules and platelet dense bodies. The most striking CHS ocular pathology observed is an enlargement of melanosomes in the retinal pigment epithelium (RPE), which leads to aberrant distribution of eye pigmentation, and results in photophobia and decreased visual acuity. Understanding the molecular function of LYST and identification of its interacting partners may provide therapeutic targets for CHS and other diseases associated with the regulation of LRO size and/or vesicle trafficking, such as asthma, urticaria and Leishmania amazonensis infections. Adv Exp Med Biol 2016; 854:745-50.
Recommended Citation
Ji X,
Chang B,
Naggert JK,
Nishina PM.
Lysosomal Trafficking Regulator (LYST). Adv Exp Med Biol 2016; 854:745-50.